C
Claude Negrier
Researcher at Claude Bernard University Lyon 1
Publications - 289
Citations - 12023
Claude Negrier is an academic researcher from Claude Bernard University Lyon 1. The author has contributed to research in topics: Haemophilia & Haemophilia A. The author has an hindex of 51, co-authored 278 publications receiving 10330 citations. Previous affiliations of Claude Negrier include Geneva College & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Johannes Oldenburg,Johnny Mahlangu,Benjamin Kim,Christophe Schmitt,Michael U. Callaghan,Guy Young,Elena Santagostino,Rebecca Kruse-Jarres,Claude Negrier,Craig M. Kessler,Nancy Valente,Elina Asikanius,Gallia G. Levy,Jerzy Windyga,Midori Shima +14 more
TL;DR: Empicizumab prophylaxis was associated with a significantly lower rate of bleeding events than no proPHylaxis among participants with hemophilia A with inhibitors and resulted in a bleeding rate that was significantly lower by 79% than the rate with previous bypassing‐agent prophylum.
Journal ArticleDOI
Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography.
L. Rugeri,A. Levrat,Jean-Stéphane David,E. Delecroix,Bernard Floccard,A. Gros,Bernard Allaouchiche,Claude Negrier +7 more
TL;DR: ROTEM is a point‐of‐care device that rapidly detects systemic changes of in vivo coagulation in trauma patients, and it might be a helpful device in guiding transfusion.
Journal ArticleDOI
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
Johnny Mahlangu,Johannes Oldenburg,Ido Paz-Priel,Claude Negrier,Markus Niggli,M Elisa Mancuso,M Elisa Mancuso,Christophe Schmitt,Víctor Jiménez-Yuste,Christine L. Kempton,Christophe Dhalluin,Michael U. Callaghan,Willem Bujan,Midori Shima,Joanne I. Adamkewicz,Elina Asikanius,Gallia G. Levy,Rebecca Kruse-Jarres +17 more
TL;DR: Empicizumab prophylaxis administered subcutaneously once weekly or every 2 weeks led to a significantly lower bleeding rate than no proPHylaxis among persons with hemophilia A without inhibitors; more than half of the participants who received prophYLaxis had no treated bleeding events.
Journal ArticleDOI
The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study.
TL;DR: In this article, the authors used Recombinant Factor VIIa (RVIIIa) as first-line therapy for 14 bleeding episodes and as salvage-therapy for 60 episodes which failed to respond to blood-product therapy given for a median of four days (range 1-21 days).
Journal ArticleDOI
Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients.
Albrice Levrat,A. Gros,L. Rugeri,Kenji Inaba,Bernard Floccard,Claude Negrier,Jean-Stéphane David +6 more
TL;DR: ROTEM provided rapid and accurate detection of hyperfibrinolysis in severely injured trauma patients and helped identify patients more severely injured than expected.